MS4A1 and B-cell chronic lymphocytic leukemia: Another advantage of GoF C2 mutant was potentiation of CDC exerted by type I anti-CD20 mAbs toward resistant CLL cells (Figure 2E,F) as well as an ability to release substantial CDC from antibodies characterized by a weak potential of complement activation (Figure 4).